فهرست نشریات علمی دسترسی آزاد ایران

Introduction: Bone metastases are a frequent complication in various tumors such as prostate, breast, and lung carcinoma often causing progressive pain. Bone-seeking beta-emitting radiopharmaceuticals such as samarium-153-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid ([153Sm]Sm-DOTMP) are potentially utilized for bone pain palliation.Methods: This research evaluated the radiation absorbed dose of [153Sm]Sm-DOTMP radiopharmaceutical for adult men based on biodistribution data in Wistar rats. The Medical Internal Radiation Dosimetry (MIRD) dose calculation method and the Sparks and Aydogan methodology were applied.Results: About 56% of the injected activity is accumulated on the surface of the trabecular and compact bones. Radiation absorbed doses of red bone marrow and osteogenic cells were estimated at 0.66±0.04 and 3.43±0.23 mGy/MBq, respectively. The maximum administrated activity was obtained at 43.3 MBq/kg (1.17 mCi/kg) of body weight with about 10.4 Gy absorbed dose of bone surface for a 70 kg adult man. The effective dose of [153Sm]Sm-DOTMP radiopharmaceutical was estimated at 0.14±0.01 mSv/MBq and the urinary bladder wall and kidneys absorbed doses were evaluated at about 0.20±0.02 mGy/MBq and 0.05±0.01 mGy/MBq, respectively. The urinary and gastrointestinal tracts were the next organs with the highest radiation absorbed dose as the main routes of excretion of radioactivity.Conclusion: This study showed that the radiopharmaceutical [153Sm]Sm-DOTMP can provide palliative care for bone metastases while delivering low undesired doses to surrounding normal tissues.